Eileen Koutnik-Fotopoulos

Authored Items

Panitumumab-FOLFOX4 Therapy Extends Survival in Patients with CRC without RAS Mutations

October 2013, Vol 4, No 8 - Personalized Medicine

Testing for KRAS mutations is recommended to guide treatment decisions in patients with metastatic colorectal cancer (CRC) by pointing to the patients who would most likely benefit from anti–epidermal growth factor receptor (EGFR) therapies. The KRAS mutation is a predictive biomarker of resistance to anti-EGFR therapy in this patient population. Specifically, patients with KRAS mutations in exon 2 do not benefit from this therapy and may have poor outcomes if an anti-EGFR is combined with an oxaliplatin (Eloxatin)-containing chemotherapy regimen. [ Read More ]

Panel Recommends Major Changes for Cutting Down Cancer Overdiagnosis and Overtreatment

November 2013, Vol 4, No 9 - Economics of Cancer Care

For the past 30 years, awareness and screening have led to an emphasis on the early diagnosis of cancer. The goals were to get screened and to catch cancer early to reduce the rate of late-stage disease and to decrease cancer mortality. However, improved screening has resulted in the overdiagnosis and overtreatment of cancers that are not life-threatening, without significantly decreasing the death rate from the disease. In March 2012, the National Cancer Institute (NCI) convened a meeting to review the evidence on overdiagnosis.

[ Read More ]

Genetic Test for Breast Cancer Screening Cost-Effective for Women at Intermediate Risk

March 2014, Vol 5, No 2 - Economics of Cancer Care

The American Cancer Society has recommended annual magnetic resonance imaging (MRI) as an adjunct to mammography for breast cancer screening in women who have a lifetime risk of breast cancer of approximately 25% to ?50%, as determined by models such as the Gail risk test. A new simulated clinical trial evaluated the cost-effectiveness of using 7 single-nucleotide polymorphisms (7SNPs) in combination with the Gail test to assess the cost-benefit of annual MRI screening in women at risk for breast cancer (Folse HJ, et al. Cancer Prev Res [Phila]. 2013;6:1328-1336). [ Read More ]

Challenges Facing US Cancer Care in 2014: ASCO’s First Annual Report to the Nation

May 2014, Vol 5, No 4 - Economics of Cancer Care

Advances in cancer treatment, from detection and diagnosis to drugs, surgical techniques, and new imaging capabilities, have collectively enabled many patients to live longer, healthier lives with or after cancer. However, a new landmark report, “The State of Cancer Care in America, 2014: A Report by the American Society of Clinical Oncology” (ASCO), identifies the many challenges that will impact the future delivery of cancer care (ASCO. J Oncol Pract. 2014;10:119-143). These challenges include an increasing demand for care, predicted workforce shortages, rapidly rising costs, imbalances in access to care, and an unstable practice environment. [ Read More ]

ASCO’s Annual Report: Major Advances in Oncology and the Challenge of Value-Based Care

April 2015, Vol 6, No 3 - Health Policy

Significant gains in cancer research and prevention have led to longer survival, improved quality of life, and decreased disease burden. The 2015 annual report on “Clinical Cancer Advances” from the American Society of Clinical Oncology (ASCO) outlines the biggest advances made in oncology, and for the first time designates one cancer as the Advance of the Year, as well as emphasizing the ongoing challenge of value-based care. [ Read More ]

ASCO Annual Report 2017: Immunotherapy 2.0 Advance of the Year

June 2017, Vol 8, No 3 - Value in Oncology

Advances in immunotherapy are benefiting increasing numbers of patients living with cancer. Since 2011, the FDA approved 15 immunotherapies in oncology, including 5 immunotherapy drugs in 2016. This surge of progress using cancer immunotherapy has led the American Society of Clinical Oncology (ASCO) to name “Immunotherapy 2.0” as its cancer advance of the year for a second year in a row. [ Read More ]

FDA Commissioner Outlines New Plan to Increase Biosimilars by “Balancing Innovation and Competition”

October 2018, Vol 9, No 3 - Health Policy

FDA Commissioner Scott Gottlieb, MD, discusses the recent release of the FDA’s 11-part action plan to boost biosimilar development, noting that biosimilar competition is “anemic because litigation has delayed market access for biosimilar products that are, or shortly will be, available in markets outside the U.S. several years before they’ll be available to patients here.” [ Read More ]

Call to Action: Greater Focus on Metastatic Cancer Survivors Is Needed

June 2019, Vol 10, No 3 - Metastatic Cancer

Two cancer experts at Johns Hopkins Kimmel Cancer Center in Baltimore, MD, are advocating for greater focus on metastatic cancer survivorship and its impact on those living with incurable cancer, a situation they know all too well. Both are living with metastatic cancer and are urging the medical community to increase the study and awareness of this condition and improve the lives of this growing population. [ Read More ]